PUTTING OUR POWER BEHIND A POTENTIALTREATMENT FOR ALS
Cytokinetics is developing tirasemtiv, a novel skeletal muscle troponin activator, as a potential treatment for people living with ALS and certain other debilitating diseases and conditions associated with muscle weakness and fatigue or neuromuscular dysfunction.
Calcium is a key regulator of muscle contraction. Tirasemtiv selectively activates the fast skeletal muscle troponin complex and increases its sensitivity to calcium, resulting in increased skeletal muscle force and power while delaying the time to muscle fatigue.
Tirasemtiv is currently the subject of a large, international Phase 3 clinical trial, called VITALITY-ALS, designed to assess its effects versus placebo on measures of respiratory function and muscle strength in people with ALS.